SylamoreBio

Sylamore Bio is a Cambridge-based biotechnology company focused on the discovery and development of RNA-targeted therapeutics. The company utilizes its proprietary Sylamore bioinformatics platform to identify and validate novel microRNA targets and regulatory motifs within the genome. This computational approach allows for the precise mapping of small RNA interactions, facilitating the design of highly specific therapeutic interventions. Sylamore Bio's primary research efforts are directed toward indications in oncology and rare genetic diseases where RNA regulation plays a critical role. The firm was founded by pioneers in bioinformatics from the University of Cambridge and the Wellcome Sanger Institute. By bridging the gap between advanced sequence analysis and drug development, the company aims to create a new class of precision medicines.